1. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405
2. Bain BJ, Gilliland DG, Horny HP, Vardiman JW (2008) Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 68–73
3. Bain BJ, Gilliland DG, Vardiman JW, Horny HP (2008) Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Hrsg) WHO classification of haematopoietic and lymphoid tissues. IARC Press, Lyon, S 51–53
4. Bartels S, Lehmann U, Büsche G, Schlue J, Mozer M, Stadler J, Triviai I, Alchalby H, Kröger N, Kreipe H (2015) SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia 29:253–255.
https://doi.org/10.1038/leu.2014.277
5. Bartels S, Faisal M, Büsche G, Schlue J, Kreipe H, Lehmann U (2018) Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. Leukemia 32:556–558